A single-centre experience of 29 total ankle replacement in haemophiliac patients: Therapeutic management, factor consumption and cost.
Favrelle L, Masson JB, Parat S, Carre E, Fessy M, Rioufol C, Lienhart A, Chamouard V, Besse JL.
Pharmacy Education and Clinical Pharmacy Training in France.
Ranchon F, Chanoine S, Anepc Pedagogical Committee, Dupuis A, Grimandi G, Sève M, Honoré S, Allenet B, Bedouch P.
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
Azaïs H, Brochard C, Taly V, Benoit L, Ferron G, Ray-Coquard I, You B, Abadie-Lacourtoisie S, Lebreton C, Venat L, Louvet C, Favier L, Blonz C, Dohollou N, Malaurie E, Dubot C, Kurtz JE, Pujade-Lauraine E, Rouleau E, Leary A, Bats AS, Blons H, Laurent-Puig P.
Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
Kamrava MR, Gonzalez-Martin A, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick C, Lorusso D, Freyer G, O’Malley DM, York W, Malinowska IA, Monk BJ.
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib.
Barnicle A, Ray-Coquard I, Rouleau E, Cadoo K, Simpkins F, Aghajanian C, Leary A, Poveda A, Lheureux S, Pujade-Lauraine E, You B, Ledermann J, Matulonis U, Gourley C, Timms KM, Lai Z, Hodgson DR, Elks CE, Dearden S, Egile C, Lao-Sirieix P, Harrington EA, Brown JS.
Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: review and current progress.
Tchernonog E, Moignet A, Anota A, Bernard S, Bouguet G, Colin F, Rioufol C, Ysebaert L, Gyan E.
Attributes for a discrete-choice experiment on preferences of patients for oncology pharmacy consultations.
Damerval M, Bennani M, Rioufol C, Omrani S, Riboulet M, Etienne-Selloum N, Saint-Ghislain A, Leenhardt F, Schmitt A, Simon N, Clairet AL, Meurisse A; French Implication Expert Panel; Nerich V.
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs.
Martin T, Rioufol C, Favier B, Martelli N, Madelaine I, Chouaid C, Borget I.
Cost-effectiveness of the ONCORAL multidisciplinary programme for the management of outpatients taking oral anticancer agents at risk of drug-related event: protocol for a pragmatic randomised controlled study.
Huot L, Guerre P, Descotes G, Caffin AG, Herledan C, Ranchon F, Rioufol C.
Eliminating the need for preoperative intravenous hyperhydration: Sodium thiosulfate as nephrotoxicity prevention in HIPEC-treated patients – A retrospective analysis.
Vachez E, Kefleyesus A, Bakrin N, Ranchon F, Rioufol C, Vassal O, Al-Hadeedi O, Kepenekian V, Glehen O.
Effectiveness and safety of an innovative silicone extender in suture reinforcement or dermatotraction: a retrospective study.
Yailian AL, Carré E, Rioufol C, Thomas L, Beatrix O.
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer.
Perez-Fidalgo A, Schmalfeldt B, George A, Gourley C, Pignata S, Lorusso D, Barretina-Ginesta MP, Romero I, Grimm C, Van Gorp T, Rossing M, Collins DC, Fernebro J, Bjørge L, Leary A, de la Motte Rouge T, Harter P, Kurzeder C, Savva-Bordalo J, You B.